We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Annual Meeting Offers Industry Education and Entertainment

By LabMedica International staff writers
Posted on 08 Jun 2017
Image: Genome editing with CRISPR-Cas9 offers the potential to treat human genetic disease (Photo courtesy of Feng Zhang).
Image: Genome editing with CRISPR-Cas9 offers the potential to treat human genetic disease (Photo courtesy of Feng Zhang).
Registration has opened for the 2017 annual meeting of the American Association of Clinical Chemistry, which has promised novel and interesting sessions that will highlight emerging science, practices, and technologies across the spectrum of clinical laboratory medicine.

The 69th AACC Annual Scientific Meeting & Clinical Lab Expo will be held in San Diego, CA, USA, from July 30 to August 3. In addition to a strong lineup of plenary speakers, which will be headed by Dr. Jennifer Doudna, professor of chemistry and molecular and cell biology at the University of California, Berkeley (USA) – who will be speaking about advances in CRISPR/Cas9 gene editing technology – there will be a mock courtroom session and two quiz games.

The mock trial session will illustrate the importance of expert witness testimony in resolving litigation associated with toxicology and clinical laboratories. One quiz game will pit the AACC leadership against members of the Society for Young Clinical Laboratorians. The teams will contest various laboratory medicine topics such as oncology and cardiovascular biomarkers, molecular testing, point-of-care testing, therapeutic drug management/toxicology, and over-utilized or outdated tests.

The second quiz game will engage the audience on topics addressing Zika virus, mass spectrometry, antimicrobial resistance, and other infectious disease issues and diagnostic solutions.

A highlight of the conference will be the Qualcomm Tricorder XPRIZE special session. Two participants in this $10 million global competition to develop devices capable of diagnosing at least 13 health conditions and continuously monitoring five vital signs, all with a consumer-friendly interface and weighing no more than five pounds (2.27 kilograms), will present their innovations.

Related Links:
AACC Annual Scientific Meeting & Clinical Lab Expo
University of California, Berkeley

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automated Clinical Chemistry Analyzer
Envoy 500+
POC Immunoassay Analyzer
Procise DX

Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more